We report a series of hybrid oxoazetidine conjugated thiazoles as epidermal growth factor receptor (EGFR) inhibitors, which were synthesized and tested using a variety of in silico and in vitro studies. The compounds were found to be active against breast and hepatic cancer cell lines, with Compounds 7a, 7b, and 7e being the most potent ones. The derivatives were also evaluated for molecular docking and complementarity studies to explicate fundamental substituent groups essential for their bioactivity. Moreover, the structural activity relationship of the analogues was performed for future compound optimization. These studies advocated that the analogues have a high affinity towards EGFR with favorable anticancer potential.The study advised that the derivatives have potency against breast and hepatic cancer and can assist as an initial scaffold for further development of anti-EGFR compounds.antitumor activity, hybrid oxoazetidine conjugated thiazoles, rational drug design
| INTRODUCTIONCancer, a malignant disease, is the leading cause of death worldwide, and due to this millions of people lose their lives each year. [1] World Health Organization (WHO) propounded that the spread of cancers is higher in low-and middle-economic countries. [2,3] WHO official webpage [4] stated that cancer was accountable for 10 million deaths in 2020. It is also noted that patients with cancer have been impacted considerably due to increased morbidity and mortality from COVID-19 infection and delays in cancer therapy. [5] Much literature illustrates that numerous enzymes are intricate in signal recognition, transduction, and amplification followed by cell growth and division but among them, tyrosine kinases (TKs) are contemplated as one of the most important ones. [6,7] TKs generally participate in cell proliferation, metabolism, and apoptosis. Therefore, disturbance in TKs function leads to tumor growth and progression. [8] Functionally, TKs can be classified either as epidermal growth factor receptor (EGFR) or nonreceptor kinases. [9] EGFR belongs to the erbB/HERfamily of TKs, which is a transmembrane protein. These receptors comprise an extracellular ligand-binding domain, cysteine-binding domain, intracellular domain, and alpha-helix transmembrane domain with TK activity within the carboxy terminus (except for HER3). [10] EGFRs contribute to the regulatory molecular transcription through cell proliferation, differentiation, apoptosis, invasion, and angiogenesis followed by organ development. In tumor cells, EGFR signaling is changed, frequently develops dysregulated, and overexpresses and/ or obtains a gain-of-function mutation. [11][12][13][14][15][16] This performance facilitates the proliferation of tumor cells and invasion of the